» Articles » PMID: 34844645

Importance of Medication Reconciliation in Cancer Patients

Overview
Date 2021 Nov 30
PMID 34844645
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer patients are a complex and vulnerable population whose medication history is often extensive. Medication reconciliations in this population are especially essential, since medication discrepancies can lead to dire outcomes. This commentary aims to describe the significance of conducting medication reconciliations in this often-forgotten patient population. We discuss additional clinical interventions that can arise during this process as well. Medication reconciliations provide the opportunity to identify and prevent drug-drug and herb-drug interactions. They also provide an opportunity to appropriately adjust chemotherapy dosing according to renal and hepatic function. Finally, reconciling medications can also provide an opportunity to identify and deprescribe inappropriate medications. While clinical impact appears evident in this landscape, evidence of economic impact is lacking. As more cancer patients are prescribed a combination of oral chemotherapies, intravenous chemotherapies and non-anticancer medications, future studies should evaluate the advantages of conducting medication reconciliations in these patient populations across multiple care settings.

Citing Articles

Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL.

Mascolo A, Di Napoli R, Balzano N, DAlessio E, Izzo I, Rossi F Front Pharmacol. 2023; 14:1229304.

PMID: 37654615 PMC: 10467285. DOI: 10.3389/fphar.2023.1229304.


Managing Drug Interactions With Oral Anticancer Treatments.

Lohr L, Blake K, Chan C, Sturm S, Walsh G J Adv Pract Oncol. 2023; 14(5):419-438.

PMID: 37576366 PMC: 10414528. DOI: 10.6004/jadpro.2023.14.5.7.


Geographic Variations and the Associated Factors in Adherence to and Persistence with Adjuvant Hormonal Therapy for the Privately Insured women Aged 18-64 with Breast Cancer in Texas.

Kim J, Kim M, Rajan S, Du X, Franzini L, Kim T Curr Oncol. 2023; 30(4):3800-3816.

PMID: 37185401 PMC: 10136640. DOI: 10.3390/curroncol30040288.


Pharmacokinetics of Herb-Drug Interactions of Plumbagin and Tazemetostat in Rats by UPLC-MS/MS.

Li H, Wang Y, Geng X, Kang Y, Wang Y, Qiu X Drug Des Devel Ther. 2022; 16:3385-3394.

PMID: 36199632 PMC: 9529013. DOI: 10.2147/DDDT.S384156.

References
1.
Nightingale G, Hajjar E, Guo K, Komura S, Urnoski E, Sendecki J . A pharmacist-led medication assessment used to determine a more precise estimation of the prevalence of complementary and alternative medication (CAM) use among ambulatory senior adults with cancer. J Geriatr Oncol. 2015; 6(5):411-7. DOI: 10.1016/j.jgo.2015.07.003. View

2.
Laube E, Yu A, Gupta D, Miao Y, Samedy P, Wills J . Rivaroxaban for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Active Cancer. Am J Cardiol. 2017; 120(2):213-217. PMC: 5523442. DOI: 10.1016/j.amjcard.2017.04.009. View

3.
Weingart S, Cleary A, Seger A, Eng T, Saadeh M, Gross A . Medication reconciliation in ambulatory oncology. Jt Comm J Qual Patient Saf. 2008; 33(12):750-7. DOI: 10.1016/s1553-7250(07)33090-0. View

4.
OMahony D, OSullivan D, Byrne S, OConnor M, Ryan C, Gallagher P . STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2014; 44(2):213-8. PMC: 4339726. DOI: 10.1093/ageing/afu145. View

5.
Whitman A, DeGregory K, Morris A, Mohile S, Ramsdale E . Pharmacist-led medication assessment and deprescribing intervention for older adults with cancer and polypharmacy: a pilot study. Support Care Cancer. 2018; 26(12):4105-4113. PMC: 6204077. DOI: 10.1007/s00520-018-4281-3. View